Moreover, augmenting these cells through different DMTs such as IFN-β, DMF, or alemtuzumab [27] and restoring their immunoregulatory activity is associated with weaker inflammatory responses and disease amelioration, which might point to NKs as future biomarkers of treatment efficacy in MS. This evidence concerns the gene IFNB1 and myeloid sarcoma.